FROM SARALASIN TO SARTANS: HISTORY OF THE ANGIOTENSIN II RECEPTOR BLOCKADE


Cite item

Full Text

Abstract

The article presents the history of development of angiotensin II receptor blockers and experience of their use in controlled clinical studies

References

  1. Basso N., Terragno N.A. History about the discovery of renin-angiotensin system. Hypertension 2001; 38: 1246-1249.
  2. Braun-Menendez E., Fasciolo J.C., Leloir L.F. et al. The substance causing renal hypertension. J. Physiol. 1940; 98: 283-298.
  3. Page I.H., Helmer О.H. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J. Exp. Med. 1940; 71: 29-42.
  4. Braun-Menendez E., Page I.H. Suggested revision of nomenclature: angiotensin. Science. 1958; 127:242.
  5. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in venom of Bothrops jararaca. Br. J. Pharmacol. 1965; 24: 163-169.
  6. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977; 196(4288): 441-444.
  7. Pals D.T., Masucci F.D., Sipos F. A specific competitive antagonist of the vascular action of angiotensin II. Circ. Res. 1971; 29: 664-672.
  8. Castellion A.W., Fulton R.W. Preclinical pharmacology of saralasin. Kidney Int. 1979 (9 Suppl.): S11-S19.
  9. Brunner H.R., Laragh J.H., Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 1972; 286(9): 441-449.
  10. Gavras H., Gavras I., Brunner H.R. et al. Physiologic studies with saralasin in animals. Kidney Int. 1979; (9 Suppl.): S20-S28.
  11. Steiner R.W., Blantz R.C. Acute reversal by saralasin of multiple intrarenal effects of angiotensin II. Am. J. Physiol. 1979; 237(5): F386-F391.
  12. Miller E.D., Delaney T.J. Blood flow alteration induced by saralasin or sodium nitroprusside in rats. Anestesiology 1981; 54(3): 199-203.
  13. Delaney T.J., Miller E.D. Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats. Anestesiology 1980; 52(2): 154-156.
  14. Anderson D.F., Binder N.D. Short-term saralasine blockade of renal hypertension in fetal lambs. J. Physiol. 1991; 433: 383-392
  15. Ribout C., Yamaguchi N., Godin D. et al. Intracoronary administration of saralasin: effects on cardiac arrhythmias induced by ischemia and reperfusion in the anaesthetized dog. Cardiovasc. Res. 1992; 26(10): 968-972.
  16. Streeten D.H., Anderson G.H., Freiberg J.M. et al. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. N. Engl. J. Med. 1975; 292(13): 657-662.
  17. Case D.B., Wallace J.M., Keim H.J. et al. Usefulness and limitations of saralasin, a partial competetitive agonist of angiotensinogen II, for evaluating the renin and sodium factors in hypertensive patients. Am. J. Med. 1976; 60(6): 825-836.
  18. Konrads A., Meurer K.A., Hummerich W. et al. Antihypertensive effects of captopril and saralasin in essential hypertension. Am. J. Cardiol. 1982; 49(6): 1558-1560.
  19. Huland H., Bause H.W., Clausen C. et al. The influence of an angiotensin II antagonist, saralasin, given before nephrectomy, on kidney function after transplantation. A contolled prospective study. Transplantation 1983; 36(2): 139-142.
  20. Symons J.D., Stebbins C.L. Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. J. Cardiovasc. Pharmacol. 1996; 28(2): 223-231.
  21. Ip S.P., Tsang S.W., Wong T.P. et al. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas 2003; 26(3): 224-229.
  22. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
  23. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
  24. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
  25. Dickstein K., Kjekshus J.; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360(9335): 752-760.
  26. Dahlof B., Devereux R.B., Kjeldsen S.E., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
  27. Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
  28. Ogihara T., Fujimoto A., Nakao K., Saruta T.; CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert. Rev. Cardiovasc. Ther. 2008; 6(9): 1195-1201.
  29. Lindholm L., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
  30. Malmqvist K., Kahan T., Edner M., et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am. J. Cardiol. 2002; 90(10): 1107-1112.
  31. Mortsell D., Malmqvist K., Held C., et al. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J. Intern. Med. 2007; 261(5): 472-479.
  32. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертонии. Российские рекомендации (третий пересмотр). М., 2008.
  33. Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-878.
  34. Persson F., Rossing P., Hovind P. et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes. 2006; 55(12): 3550-3555.
  35. Llewelyn D.E., Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J. Renin Angiotensin Aldosterone Syst. 2004; 5(3): 141-145.
  36. Rossing K., Christensen P.K., Andersen S. et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care. 2003; 26(3): 569-574.
  37. Andersen S., Brochner-Mortensen J., Parving H.H.; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003; 26(12): 3296-3302.
  38. Palmer A.J., Annemans L., Roze S. et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care. 2004; 27(8): 1897-1903.
  39. Macfarlane D.P., Paterson K.R., Fisher M. Cardiovascular drugs as antidiabetic agents: evidence for prevention of type 2 diabetes. Diabetes Obes. Metab. 2008; 10(7): 533-544.
  40. Ernsberger P., Koletsky R.J. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr. Opin. Pharmacol. 2007; 7(2): 140-145.
  41. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
  42. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом // Сonsilium Medicum. 2006. Т. 8. № 11. С. 25-30.
  43. Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 2007; 6: 12.
  44. Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46(1): 137-143.
  45. Di Filippo C., Lampa E., Tufariello E. et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes. Res. 2005; 13(11): 1909-1914
  46. Voigt J.P., Bramlage P., Fink H. Hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan in rats. Eur. J. Pharmacol. 2007; 535: 233-237.
  47. de las Heras N., Martin-Fernandez B., Miana M. et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J. Hypertens. 2009; 27 (Suppl. 6): S37-S41.
  48. Anand K., Mooss A.N., Hee T.T., Mohiuddin S.M. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am. Heart J. 2006; 152(2): 217-222.
  49. Ehrlich J.R., Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009; 69(7): 757-774.
  50. Madrid A.H., Bueno M.G., Rebollo J.M.G. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002; 106: 331-336.
  51. Massie B.M., Carson P.E., McMurray J.J. et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008; 359: 2456-2467.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies